Legal Marijuana Companies

In January 2024, the Department of Health and Human Services (HHS) released a recommendation to reschedule cannabis from Schedule I to Schedule III. This could have significant implications for the industry, potentially opening up access to banking, research, and investment opportunities. Major cannabis stocks have surged since the recommendation's release, reflecting investor optimism about the potential for federal reform.

Multi-State Operators (MSOs), like Curaleaf, Trulieve, and Green Thumb Industries, are adopting a cautious approach to expansion in 2024. This comes amidst market saturation in some regions and ongoing regulatory hurdles. Instead of aggressive growth, MSOs are focusing on optimizing existing operations, improving profitability, and entering new markets with high-growth potential.

• Canopy Growth Corporation (US)


• GBSciences Inc.(Nevada)


• CanniMed Ltd (Canada)


• Cannabis Sativa Inc (Nevada)


• GW Pharmaceuticals Plc (US)


• Aphria (Ontario)


• Pfizer Inc. (US)


• Emerald Health Therapeutics Inc. (Victoria, BC)


• Medical Marijuana Inc (US)


• MediPharm Labs (US)